I couldn't agree with you more, but the question is which horse. With all the talk about BetonMace and the final release of the trial design etc. there appears to be a bit of ya we knew that already going on (old news). Investors expected this on Oct 21 as Don had announced earlier. Again, not meeting that date and no surprise announcements the PPS showed no response to the announcement. This is a direct result of over promising and not deleivering on time. With some activity around Zenith and the hope of some analyist releasing their reports to their investors soon, I would think there will be more interest and we should see a small increase in the PPS.

I have read a few posts talking about tax loss sell season approaching. To me this could be only positive as bio investors have been hit hard this last few months and will be taking a tax loss on those other Biotecks that have been driven down for various reasons. This will open up an opportunity for some of that money to come our way. With the exception of investors who purchased RVX in the last half of this year, most of us should be in the green for this year and will have no loss. As well, those that recognize the potential of RVX will hold on to what they have, knowing the explosive potential of this stock. They do not want to be caught out of RVX should it take off during this time. The number of shares traded in the last half 2015 is quite low as we all know and tax loss selling should be a non event in my oponion for this stock.

I am expecting an announcement of some kind of partenership with a European company in the near future. There seems to be more interest in that area of the world as opposed to here in North America. The FDA is caught up in the politics of health care and will not entertain this new class of drug until the government deals with there side of the issue. I think there is more to this then meets the eye. Could I say they drag their feet until they catch up to us.

The only horse I would let out of the barn right now if I was Don is a orphan drug trial. JMHO.